$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Medical drugs
Medical drugs
Medical drugs-Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
The development history and background of Erdafitinib
2026-02-01 22:25:32
Check Details
Is it better to take dacomitinib/dacomitinib (Dozerun) on an empty stomach or after a meal?
2026-02-01 22:25:32
Check Details
Effect of Entrectinib/Luo Shengquan Combination Chemotherapy
2026-02-01 22:25:32
Check Details
Comparison of the efficacy of brigatinib/brigatinib (Embry) and similar targeted drugs
2026-02-01 22:25:32
Check Details
What are the purchasing channels for Acalabrutinib in China?
2026-02-01 22:25:32
Check Details
sevabertinib-Hyrnuo’s Chinese instruction manual
2026-02-01 22:25:32
Check Details
Fixed-duration venetoclax combination equivalent to continuous ibrutinib in head-to-head comparison in CLL
2026-02-01 22:25:32
Check Details
The efficacy of ruxolitinib tablets/Jiekewei in treating thrombocythemia
2026-02-01 22:25:32
Check Details
What are the indications for Clofazimine?
2026-02-01 22:25:32
Check Details
How effective is Sorafenib/Nexavar in treating kidney cancer?
2026-02-01 22:25:32
Check Details
Pemetinib/Dabotan FDA approval time
2026-02-01 22:25:32
Check Details
Erdafitinib/Bocco is safe and shows preliminary efficacy in F3T3 fusion+ glioma
2026-02-01 22:25:32
Check Details
1
2
...
2295
2296
2297
2298
2299
2300
2301
...
2438
2439
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Olaparib Plus Pembrolizumab Maintenance Therapy for Metastatic Pancreatic Cancer: Findings from the POLAR Phase II Basket Trial
2
From Causes to Treatments—Exploring Medical Breakthroughs
3
IRX4 Transcription Factor: New Research Insights on Colorectal Cancer Treatment Targets
4
New Research Progress on Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Tumor Relationship
5
Tyrosine Kinase and JAK Inhibitors May Increase Keratinocyte Carcinoma Risk: New Research Reveals Drug Safety Findings
6
CLISGen Database: A New Tool for Cell Line Selection in Cancer Genetic Variation Research
7
RAS Targeted Therapy Resistance Breakthrough: mTORC1 is Key, Dalifarnib Combination Therapy Brings Hope
8
ARID1A Gene: A New Breakthrough in Tumor Immunotherapy, Turning "Cold Tumors" Hot
9
User Agreement
10
Herceptin Hylecta treats HER2-positive breast cancer and only needs to be injected subcutaneously and only used once every three weeks
11
What is the most important information I should know about WELIREG?
12
How to take and store WELIREG